Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata Reports Record Second Quarter 2026 Results6.8.2026 22:05:00 CEST | Press release
Revenue Up 58% Year-Over-Year, Beats Consensus by 7% Adjusted EBITDA of $25.4 Million, Beats Consensus by 50% Adjusted Gross Margin Expands to 49% Announces Planned Leadership Transition Effective September 30: Rahul Singhal to Become President and CEO, Jack Abuhoff to Become Executive Chairman NEW YORK, NY / ACCESS Newswire / August 6, 2026 / INNODATA INC. (NASDAQ:INOD) today reported results for the second quarter ended June 30, 2026. Revenue of $92.1 million, representing 58% year-over-year revenue growth. Adjusted Gross Profit of $45.4 million, representing Adjusted Gross Margin of 49%.* Adjusted EBITDA of $25.4 million, or 27.5% of revenue, an increase of $12.1 million from $13.2 million in the same period last year.* Net income of $14.4 million, or $0.43 per basic share and $0.41 per diluted share for the three-month period ended June 30, 2026, compared to net income of $7.2 million, or $0.23 per basic share and $0.20 per diluted share, in the same period last year. Cash, cash eq
Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook6.8.2026 14:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / August 6, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our") reported record results for the second quarter of 2026. "Through the first half of the year, the business continues to outperform our expectations, driven by exceptional demand across our end-markets and strong conversion of our new business pipeline. Of the approximately $750 million in our pipeline, we secured initial orders that provide visibility to approximately $200 million of revenue over the next five years," said Dirkson Charles, Loar Holdings Chief Executive Officer and Executive Co-Chairman of the Board of Directors. Second Quarter 2026 Net sales of $171.6 million, up 39.4% compared to the prior year's quarter. Net income of $16.7 million, equal to the prior year's quarter. Diluted earnings per share of $0.18 compared to $0.17 for the prior year's quarter. Adjusted EBITDA of $69.4 million up 47.4% compared to the prior year's quarter. Net income
RE Royalties Announces Third Investment in Solaris Energy's Portfolio and Letter of Intent for Expanded Royalty Partnership for a Further US$62.7 Million5.8.2026 12:00:00 CEST | Press release
All amounts in US dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce a further investment of US$1 million toward the purchase of royalties on a portfolio of Solaris Energy Inc.'s ("Solaris") distributed generation ("DG") solar projects located throughout the United States. The Company also announced that it has entered into a non-binding Letter of Intent ("LOI") of up to US$67.5 million with Solaris to pursue an expanded royalty funding partnership across Solaris' current and future project pipeline. This third tranche payment brings RE Royalties' total investment in royalties over Solaris' portfolio to US$4.8 million. The Company previously funded US$3 million, as announced on January 7, 2026, followed by US$800,000 as announced on February 9, 2026. Solaris' Portfolio consists of 16 distributed generation solar projects totaling approximately 15.2
Kleen Hy-Dro-Gen Inc. Is Pleased to Announce Dual ISO 9001:2015 and TSSA Certifications, Bolstering Operational Quality and Technical Safety Governance5.8.2026 02:10:00 CEST | Press release
Key regulatory and quality management accreditations position the CSE-listed clean energy technology provider for accelerated commercialization and potential major enterprise contracts to manufacture and sell, residential and commercial, Zero Emissions Heating Systems using Hydrogen as a heat energy source. TORONTO, ON / ACCESS Newswire / August 4, 2026 / Kleen-Hy-Dro-Gen Inc. (the "Company") (CSE:KLN) is pleased to announce that it has officially achieved both ISO 9001:2015 Quality Management System certification and regulatory Technical Standards and Safety Authority ("TSSA") certification for its flagship product KLEEN HEAT On-Demand Hydrogen Heating System. These dual accreditations mark a major operational milestone for the Company, establishing independent third-party verification of the Company's quality assurance framework, engineering standards, and regulatory safety compliance across its Kleen Heat technology, advancing the Company's goal of safely utilizing the system in Zer
Innodata Releases the First Stage of Its AI Cyber Training Suite to Enable AI Coding Agents to Write - and Repair - Secure Code4.8.2026 14:30:00 CEST | Press release
Twelve datasets and evaluation systems, built by hand from thousands of real-world security flaws, give model builders and enterprises a proven way to keep AI-generated code from introducing vulnerabilities. NEW YORK, NY / ACCESS Newswire / August 4, 2026 / INNODATA INC. (Nasdaq:INOD) today released the first stage of its AI Cyber Training Suite - twelve datasets and evaluation systems that train AI coding agents to write code that avoids known security flaws, to avoid introducing new ones, and to patch existing vulnerabilities in the software companies already run. The suite addresses what has become a central barrier to trusting AI-written code: the risk that an agent, while adding a feature or modernizing a legacy system, quietly opens a security hole. The AI Cyber Training Suite works across the stack of coding agents - the models, the harnesses, and the tools - to help ensure the code they produce is not just functional, but secure. It is available to model builders and enterprise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom